News | September 26, 2023
Biosergen, Alkem collaborate to develop anti-infective for severe fungal infections
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
The company has reported total income of Rs. 2971.27 crores during the period ended March 31, 2023
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
Zidavi is recommended by the Infectious Disease Society of America
Though lungs do not have the celebrity status as the heart, they are one of the most important and delicate organs of the human body
He holds a Bachelor’s Degree in Science and has joined the company in 2012 and has over 10 years of experience in pharmaceutical industry
This GMP and Pre-Approval Inspection is part of the routine business operations and the company shall submit to US FDA within the stipulated timeline
The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.
Subscribe To Our Newsletter & Stay Updated
